公司资料
Autolus Therapeutics plc 股价、新闻与催化剂
- 股票代码:
- AUTL
- 交易所:
- NASDAQ
- 行业:
- Biopharma
- 所在地:
- United Kingdom
股票表现
2.28 USD (+6.05%)
收盘价
最后更新: 2026年8月17日
466M USD
市值
股价为何变动
As of Aug 17, 2026, AUTL closed up 6.05% at $2.28. No new same-company headline was identified in the current news window.
公司概览
Programmable T-Cell Therapy Company
Autolus Therapeutics develops, manufactures, and commercializes next-generation T-cell therapies for cancer and autoimmune disease using modular cell-programming technologies.
AUCATZYL
AUCATZYL, or obecabtagene autoleucel, is an autologous CD19 CAR T-cell therapy commercialized for adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia.
Fast Off-Rate CAR Design
Obe-cel uses a fast off-rate CD19 binding domain intended to reduce excessive T-cell activation while preserving antitumor activity and persistence.
Integrated Manufacturing
Autolus controls manufacturing and product delivery, supporting launches in the United States and United Kingdom and providing infrastructure for additional cell-therapy programs.
Pipeline Expansion
The company is extending its T-cell platform into additional hematologic cancers and autoimmune disease while building on physician experience with obe-cel.
未来催化剂
- Autolus’s next catalyst is AUCATZYL commercial launch execution and any follow-on CAR-T update that proves the franchise can scale. The market is watching whether the cell-therapy rollout can translate into durable adoption.
近期新闻
- 01
- 02
- 03
- 04
- 05
相似股票
商业成熟度、治疗领域或催化剂模式相近的同行公司。